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Contemporary Approach to Thyroid Disease Emphasizing Use of
High-Sensitivity Thyrotropin Assays*

Carolyn S. Feldkamp, PhD,' and Malachi J. McKenna, MD^

Capabilities of new high-sensitivity immunoradiometric assays for thyroid-stimulating hormone
(TSH-IRMA) to distinguish among hypothyroid, euthyroid, and hyperthyroid .subjects and paUent
groups with low TSH for nonthyroidal causes suggested an algorithmic approach (directed TSH) lo
the evalualion of patients with suspected thyroid disease. Utilizing the algorithm, a TSH-IRMA result
outside normal limits (0.5 to 5.0 mUlL) generates follow-up tests on Ihe same sample. The
interpretation of thyroidfuncUon tests (TSH-IRMA. ihyro.xine. resin uptake.free thyro.xine index) and
associated studies in the context of dijferent clinical settings is reviewed. The approach is a costeffective and efficient utUizaUon of laboratory services. (Henry Ford Ho.sp MedJ 1991:39:25-9)

W

e are living in an era of cost containment necessitating
appropriate utilization of fixed resources. Tests to evaluate thyroid function have proliferated over the last three decades
and are the highest volume assays performed in the Ligand Assay Laboratory at Henry Ford Hospital. In the last few years the
analysis of thyroid-stimulating hormone (TSH) has been improved by the introduction of new technologies and the use of
monoclonal antibodies. After evaluating a number of kits that
measure TSH by the immunoradiometric methodology (TSHIRMA), we introduced a new assay to replace conventional radioimmunoassay (TSH-RIA) in 1987. The use ofthis improved
TSH assay as well as the implementation of a Pathology Department Laboratory Information System with enhanced capabilities has led us to propo.se an algorithm which diminishes the frequency of unnecessary thyroid testing. This approach to the initial evaluation of thyroid disease, incorporating the algorithm,
has been studied in several different clinical settings: states of
thyroid dysfunction, as well as thyromegalies, diffuse or nodular.

Patterns of Thyroid Testing
We reviewed the ordering pattems of thyroid function tests at
Henry Ford Hospital and satellites in an effort to optimize laboratory testing while simultaneously maintaining quality medical
care. Table 1 shows the usual frequency of thyroid tests ordered.
An evaluation of the distributions of test results in the combined
inpatient and outpatient population (Figs I and 2) revealed that
in approximately 1,000 tests neariy 78% had normal TSHIRMA and 84% had normal thyroxine (T4). Approximately onethird of all orders included both TSH-IRMA and T^. The current
ordering pattem suggests that, departing from the past recommendations to include T^, triiodothyronine (T3) resin uptake
(RU) ratio, and free thyroxine index (FTI) (T^ x RU) for initial
diagnosis, physicians now frequently order TSH-IRMA in addi-
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tion for screening, diagnosis, and follow-up. Retrospective laboratory data are not adequate to evaluate whether the test combinations being used are appropriate for all clinical situations.

Traditional Approach to
Thyroid Function Testing
A number of laboratory tests have been available for many
years: total T^; T3 resin uptake or RU ratio (resin uptake/normal
resin uptake); calculated FTI based on total T^ and RU; total T,;
free T4; free T,; basal TSH-RIA; and TSH-RIA response to thyrotropin-releasing hormone (TRH) stimulation. In the past the
most common approach to evaluation of thyroid function was to
measure total T^ and RU, the latter adjusting for the effects of
abnormalities in binding proteins. In equivocal cases of hyperthyroidism, the TSH response to TRH was measured, with a

Table I
Current Status of Thyroid Testing at Henry Ford Hospital
Test
Thyroid-stimulating hormone
Thyroxine
Resin uptake
Triiodothyronine

Number/Month

Frequency

2,800
2,500
1,000
1.50

7 days/week
Monday-Friday
Monday-Friday
1 day/week

SubmiUed I'or publication: Juiy 18, 1990.
Accepled for publication: August 30. 1990.
*Parts ofthis paper were originally presented at Medical Grand Rounds. Henry Ford Hospital. November 1989.
tDepartment of Pathology, Ligand Assay Laboratory. Henry Ford Hospital.
+Formerly Division of Endocrinology and Metabolism. Henry Ford Hospital. Currenlly
Department of Endocrinology and Diabetes. Sl. Vincent's Hospital. Dublin. Ireland.
Address correspondence lo Dr. Feldkamp, Deparlmenl of Pathology. Ligand Assay Laboralory, Henry Ford Hospital. 2799 W Grand Blvd. Detroit, Ml 48202.
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Fig 1—Percent of Henry Ford Hospital patients (inpatient and
outpatient) with low, normal, and high TSH-IRMA concentrations.
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binding proteins. Initially T^ may rise, but eventually values can
be very low, the degree of change often correlating with the severity ofthe NTI. Total T, in serum is always disproportionately
lower than T^. At the same time, there is often an increase in reverse T3, a nonfunctional metabolite, not caused by an increase
in its production but rather to a decrease in its clearance from serum. The more severe the illness, the lower the T^ becomes. The
reverse T3 level is inversely related to patient survival. TSHRIA is usually within the normal range in NTI, although highsensitivity assays have reported both very low values or occasional high values in the acute illness.
Close inspection of the RU result often allows discrimination
between NTI and intrinsic thyroid disease. In hyperthyroidism,
thyroxine-binding globulin (TBG) is saturated and few binding
sites remain, so the RU is elevated. Calculated FTI is higher than
total T4. In hypothyroidism the converse is found: TBG is unsaturated, RU is low, and calculated FTI is lower than total T4. On
the other hand, for NTl, there is an apparent saturation of TBG
as a consequence of putative inhibitors to binding, along with
low TBG levels, and RU is elevated. Calculated FTI exceeds the
measured total T4. The main conclusion for the clinician interpreting T4 levels in patients with severe illnesses is the importance of recognizing the direction of changes in T4 and RU for
both hypothyroidism and NTI. In hypothyroidism the FTI is
lower than the total T4, but in NTI the total T4 is lower than the
FTI. Also, it is important to emphasize that the FTI result in NTI
is frequently not corrected to the normal range.
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Fig 2—Percent of Henry Ford Hospital patients (inpatient and
outpatient) with low. normal, and high T. concentrations.

lack of response being indicative of thyrotoxicosis. In instances
of suspected hypothyroidism, a single TSH-RIA was sufficient
to make a diagnosis of primary hypothyroidism; a TRH stimulation was sometimes required to evaluate cases of central hypothyroidism but did not always elucidate the cause. Rarely were
determinations of total T,, free T^, or free T3 necessary for complete evaluation.
The traditional approach had limitations because several conditions simulated the biochemical features of hyperthyroidism
and hypothyroidism, the most common example in hospitalized
patients being nonthyroidal illness (NTI), termed "euthyroid
sick syndrome." Nearly all serious illnesses give rise to changes
in T4. There are two prominent abnormalities: 1) impaired 5'monoiodination leading to impaired peripheral conversion of T^
to T3, and 2) an inhibition of binding of thyroid hormones to
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New Approach to Thyroid
Function Testing Using TSH-IRMA
State-of-the-art assays for TSH are variably called TSHIRMA, "sandwich" TSH, or "high-sensitivity" TSH. The latter
refers to contemporary immunoassays being able to detect TSH
at concentrations which are orders of magnitude lower than concentrations measured by RIA.
Use of new TSH-lRMAs in the initial evaluation of patients
offers an approach that should be superior in terms of diagnostic
accuracy and cost effectiveness (1-5). The level of TSH in semm
reflects the pituitary response to ambient thyroid hormone concentration. TSH measured by conventional RIA did not have the
analytical sensitivity to distinguish reduction in TSH secretion
from normal. The TSH-IRMA, a high-sensitivity assay, can detect very low concentrations and does make this distinction. In
the natural history of primary thyroid dysfunction, serum TSH
values become abnormal much sooner than serum T4. The laboratory reference range for total T4 is broad, and T4 values within
the normal range may be found in patients with both hyperthyroidism and hypothyroidism. Accordingly, it has been suggested by some authorities that TSH, measured by a high-sensitivity assay, is the preferred initial test of thyroid function.
Principle of TSH-IRMA
The principle of immunoradiometric assays is illustrated in
Fig 3. A characteristic feature ofthese assays is that two different, specific (often monoclonal) antibodies directed toward two
different antigenic sites on the TSH molecule are used to create
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Fig 3—Diagram ofthe principle of the IRMA technique in which
a TSH molecule containing a and |3 subunits forms a "sandwich" between two antibodies specific for a and P subunits.
Awr/-p is radiolabeled (*).

a "sandwich" with TSH between. The first antibody is often
bound to a solid phase material such as a plastic bead, a magnetic particle, or the inside of a test tube that serves as a mechanism for physically separating the TSH from the sample solution. After the first antibody has extracted the analyte of interest
from the sample, the second antibody directed toward a different
antigenic site is added, forming the sandwich. The second antibody is labeled with some detectable moiety such as a radioactive atom like '-•''iodine, an enzyme, or afluorescentmolecule.
The measured label increases linearly over a wide range of concentrations.
These assays tend to be specific because of the use of monoclonal antibodies and because only molecules which contain
both antigenic sites can be detected. High sensitivity is obtained
because the labels used can be detected in very low amounts and
because both antibodies are in excess. Sensitivity is limited only
by the amount of sample used in the measurement, nonspecific
interference, and instrument noise in detection of the label. Excess reagent conditions in a chemical reaction also increase the
rate of reaction. Thus, these assays are relatively fast, a few minutes of reaction time in contrast with the several days needed in
the early days of RIA.
The immunoradiometric assay format can be contrasted with
RIA which also uses a specific antibody-antigen reaction to measure a biological molecule. RIA uses a limited amount of a single antibody and a labeled antigen which competes with the antigen in the patient sample for binding to antibody binding sites.
The measured response is inversely and nonlinearly related to
concentration. Both assay types have analytical strengths and
weaknesses and both have a role in the clinical laboratory, depending on the specific application.
Precision profile and sensitivity
In any chemical assay there is some error associated with
measurement, and immunoassays are no exception. Typically a
measurement error is expressed as coefficient of variation (CV),
i.e., standard deviation divided by the mean of the measurement.
For immunoassays, CV increases at very high and low concentrations. Sensitivity in an analytical sense means how low a concentration can be measured before the error is intolerable. A precision profile (Fig 4) is a graph of measured CV versus concentration. The working range of an assay can be defined as the
range of concentration with CV less than a predefined level.
Typically a CV of 10% or less is considered desirable for immu-
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Concentration
Fig 4—Diagram ofa precision profile which relates interassay
precision (CV) with concentration of analyte. The assay working range is defined as the concentration range with an acceptably low CV.
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Fig 5—Diagram ofthe precision profile of TSH assays as technical changes have improved assay precision. (From Spencer
CA. Thyroid profiling for the 1990s: Free T4 estimate on sensitive TSH measurement. J Clin Immunoassay 1989;12:85. Reprinted with permission.)

noassay. As assay sensitivity improves, the precision profile
shifts to the left. The difference between IRMAs (second- and
third-generation assays) compared to RIA (first-generation immunoassay) is illustrated in Fig 5 (6).
An alternative method of expressing analytical sensitivity is
to define the "least detectable dose" (LDD). LDD is defined as
the lowest concentration that is .not zero at a 95% confidence
level. That is, the measured response is > 2 standard deviations
from that of a sample with none of the analyte of interest. The
CV for a zero standard in the LDD experiment is usually quite
low since the measurement is made on a single laboratory-prepared zero standard, and thus it may give an overly optimistic
estimate of the sensitivity of an assay. Also, use of LDD does
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Table 2
Clinical Interpretation of Low TSH Levels
Clinical Cla.ssification

<0,l

Graves' disease
L-thyroxine
Nonthyroidal illness

>0,1 to < 0,2

6(100%)
.31 (77%)
0 (0%)

0(0%)
9(2.3%)
6(l00%i)

i,,ne, 1 Ul LiiiiiLai Llassijitaiion Ol paiienis wun low i:5H-IKMA concenlralions, patients were grouped inlo those with Graves" disease, those being treated with L-thyroxine
for replacement or suppression, and those who had a nonthyroidal illness lowering TSHIRMA, LDD was 0,04 mU/L: the lower reporting limit was 0,1 mU/L; n = 52,

DRTSH:

A

Thyroid

Testing

Algorithm

TSH

1

0,4

5,5

N.R,
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> 5,0

<
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No

other
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Thyrotoxicosis
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Secondary
hypothyroid

Subclinical

Primary

hypothyroid

hypothyroid

Fig 6—A computer-directed thyroid testing algorithm (DRTSH).
The initial test is TSH-IRMA. Patient results outside .specified
limits initiate follow-up T_,. RU. and calculated FTI. Diagnostic
clas ses are defined as described in the text. NR = normal ran^e.

not reflect that very low concentrations in patient samples near
the LDD also have significant measurement error which may
overiap the 95% confidence limits ofthe zero.
Experience with TSH-lRMAs has led many laboratories to
define "laboratory sensitivity" as a concentration somewhere
between the LDD and the low end of the euthyroid range. This
defines the lower reporting range. Results below the lower reporting range are considered undetectable. Third-generation assays are being developed to detect even lower concentrations,
having reported LDD of 0.003 mU/L and CV of 3.9% at 0.05
mU/L (5).

Clinical application of highly sensitive TSH
TSH-lRMAs distinguish between hyperthyroid and euthyroid individuals (1-5,7). In addition, the increased sensidvity
also allows identification of patients who are not clinically hyperthyroid but have decreased but detectable TSH (0.1 to 0.4
mU/L) (5). A variety of conditions can account for these test results, and careful interpretation by the physician is required.
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To confirm the diagnostic specificity and sensitivity of the
TSH-IRMA and to establish an effective lower reporting limit,
we reviewed the clinical status of 52 patients (Table 2) whose
TSH-IRMA concentrations fell between the LDD (0.04 mU/L)
and the previous lower reporting limit of < 0.2 mU/L. The patients were classified by TSH-IRMA concentration as < 0.1
mU/L or between 0.1 and 0.2 mU/L.
All ofthe patients with Graves' disease (six in this group) had
TSH-IRMA < 0.1 mU/L. As expected, many of the patients in
the group were being treated with thyroxine; their TSH-IRMA
results varied from the LDD to 0.2 mU/L. Six patients, all with
low but detectable TSH, had a NTI or were receiving therapy
known to lower TSH-IRMA such as glucocorticoids or dopamine. Though in this limited study all patients with NTI fell in a
detectable range (0.1 to 0.2 mU/L), others have reported undetectable TSH-IRMA in NTl (6.9%) (8) and a poor correlation
between FTI and TSH concentration in this group. When an
even more sensitive assay was used, there appeared to be meaningful distinction between hyperthyroid patients (< 0.1 mU/L)
and patients with either NTl or who were receiving thyroxine
(>0.1 mU/L)(6).
Proposed algorithm for thyroid function testing
The following advancements have allowed us to propose an
algorithm for thyroid function testing:
1. TSH-IRMA, a highly sensitive technique, allows measurement of hormione levels lower than those detectable by conventional RIA.
2. The lower reporting range of TSH, less than 0.1 mU/L,
identifies a category of patients with TSH lower than normals,
herein designated as low (0.1 to 0.4 mU/L), in addition to the undetectable category.
3. The laboratory computer system permits automatic ordering of subsequent tests based on the results of the initial TSH
assay.
A computer-directed algorithm for thyroid testing, termed directed TSH (DRTSH), is defined in Fig 6. Initially. TSH-IRMA
is measured. If the result falls within specified limits, the results
are reported and no further testing is done. Although the normal
range is 0.4 to 5.5 mU/mL. the cut-off limits for the purpose of
the algorithm were set to overiap with the extremes of normal
range, i.e., 0.5 to 5.0 mU/L. If the results are < 0.5 mU/L or > 5.0
but < 10.0 mU/L, total T4 and RU will be determined on the
same specimen and reported along with a calculated FTI (T4 x
RU). This conservative approach may generate some additional
follow-up testing but reduces the concem about missing appropriate follow-up in borderline cases. An upper limit of 10.0
mU/L was chosen because TSH higher than 10 mU/L rarely occurs with conditions other than hypothyroidism. The follow-up
tests often clarify the cause of the low or high TSH and may
identify the need for additional studies.
Fig 6, which depicts the use of TSH-IRMA as a screening
test, indicates possible interpretation of test results. A normal
TSH-IRMA value indicates normal function and precludes the
need for further tests. An "abnormal" result (outside preset
limit) suggests a potential need for further testing, namely total
T4 and RU. High TSH-IRMA in conjunction with low FTI is
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typical of primary hypothyroidism. In the rare instance of high
TSH with high FTI, test results suggest either a thyroid hormone
resistant state or TSH-secreting tumor, Lxiw TSH-IRMA with
high or high-normal FTI is consistent with hyperthyroidism,
thyroiditis, or therapy with L-thyroxine. Low TSH-IRMA with
low-normal or low FTI is consistent with a NTl or central hypothyroidism. Hypothyroidism due to hypothalamic or pituitary
disease is rare compared to the prevalence of NTI. TSH-IRMA
concentration in this setting may be either low or within the normal range; in the latter instance the result would not generate follow-up tests and the correct diagnosis could be missed.
Should both TSH-IRMA and T4 be low, NTI must be distinguished from central hypothyroidism. RU should give diametric
results in central hypothyroidism and NTI and thus readily distinguish between the two. The diagnosis of central hypothyroidism may be corroborated with other endocrine studies of hypothalamic pituitary function.
Employing this new approach to thyroid function testing is
not without limitations (Table 3) (4). The major caveat is the
likelihood of not detecting hypothyroidism due to hypothalamic-pituitary disease. Also, TSH-producing pituitary adenomas resulting in hyperthyroidism may have a normal TSHIRMA value. Although thyroid dysfunction due to disease ofthe
hypothalamic-pituitary area is rare, in clinical practice the diagnosis must not be missed. Certain medications such as steroids
and dopamine can lower serum TSH. Acute psychiatric illnesses, mainly of the psychotic type, are also associated with
low TSH-IRMA values; indeed, a state of transient hyperthyroidism may occur. Finally, NTl, particularly when severe, may
lead to lowering of TSH-IRMA values. There may be other circumstances of low TSH-IRMA yet to be identified as experience with the new assays accumulates. In order to facilitate interpretation of TSH-IRMA values below the lower limit of normal, we favor distinction between two categories: "low" when
the value is below the lower limit of normal but above the undetectable level, and "undetectable" when the result is below the
lower reporting limit. It is our experience that undetectable values are almost always associated with hyperthyroidism. On the
contrary, low TSH values may be caused by a variety of conditions but rarely, if ever, by hyperthyroidism. Testing the TSH response to TRH stimulation continues to have significance in the
evaluation of difficult cases.
Adopting this approach to thyroid function testing requires an
understanding of the benefits and limitations. Undoubtedly, diagnostic accuracy and efficiency of testing are substantially improved. Nonetheless, at the end of the day, clinical judgment is
required when reaching a diagnosis.

Advantages and Cautions
to Use of the Algorithm
The algorithm cannot be understood as one-step diagnosis.
Rather, it is an efficient method of obtaining appropriate laboratory tests. Although frank hypothyroidism and the euthyroid
state may be relatively easy to identify, thyroid tests must still be
interpreted in concert with one another and in the clinical context. Physicians must distinguish between low and undetectable
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Table 3
Caveats of High-Sensitivity TSH Assays
Hypolhalamic/pituilary disease
Severe nonthyroidal illness
Drug therapy (i,e,, dopamine, glucocorticoid)
Acute psychiatric illness
Recovery following radioiodine therapy for
hypothyroidism or hyperthyroidism

TSH-IRMA and be aware of nonthyroidal conditions and therapies which may affect TSH-IRMA results. In particular, patients
with severe NTl may have abnormal thyroid function tests
which may not be resolved until the underlying disease is improved.

Conclusion
Thyroid disease in all its forms is common in clinical practice. The intemist has a vast array of tests available for use in
guiding management. Adopting DRTSH diminishes the number
of unnecessary tests. Some cases, despite a reliable approach,
remain inscrutable and require expert evaluation. By choosing
this simplified approach to the use and interpretation of thyroid
function tests, the physician can identify cases that need more
detailed study. The algorithm is by no means a substitute for
sound clinical judgement; findings in an individual case must
always be tempered by a physician's intuition and experience.
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